CRBP Latest Press Releases

-- November 5, 2026 --

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in November Globe Newswire 8:00 AM

-- October 22, 2026 --

Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week 2026 Globe Newswire 8:00 AM

-- September 29, 2026 --

Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer Globe Newswire 8:00 AM

-- September 14, 2026 --

Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity Globe Newswire 7:00 AM

-- September 11, 2026 --

Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity Globe Newswire 4:01 PM

-- August 17, 2026 --

Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 10:00 AM

-- August 6, 2026 --

Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update Globe Newswire 8:00 AM

-- August 4, 2026 --

Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity Globe Newswire 8:30 AM

-- July 28, 2026 --

Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer Globe Newswire 8:00 AM

-- July 6, 2026 --

Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes